Could Chinese pharmaceutical companies help mass-produce certain drugs to strengthen the global fight against COVID-19 that is already in its third year, and thus show that their products can be game-changers? Such a question won't be dismissed in a jiffy anymore, industry insiders said.
HONG KONG If investors in China’s biotech industry needed one more sign that the sector is coming of age, then a major licensing deal RemeGen Co Ltd struck…
If investors in China's biotech industry needed one more sign that the sector is coming of age, then a major licensing deal RemeGen Co Ltd (9995.HK) struck last month with Seattle-based Seagen Inc fits the bill.
Analysis-China's biotech sector comes of age with big licensing deals, global ambitions netscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from netscape.com Daily Mail and Mail on Sunday newspapers.